When GLP-1 hits the liver: a novel approach for insulin resistance and NASH (original) (raw)

Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential

Alessandra Musio, Maria Letizia Petroni, Hepatoma Research, Giulio Marchesini

Hepatoma Research, 2020

View PDFchevron_right

Non‑alcoholic fatty liver disease: A major challenge in type�2 diabetes mellitus (Review)

Roxana Stoica

Experimental and Therapeutic Medicine, 2020

View PDFchevron_right

Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD

Mauro Maurantonio

Current Pharmaceutical Design, 2013

View PDFchevron_right

Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD

Manuela Vitulo

International Journal of Molecular Sciences

View PDFchevron_right

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD

Dunja Igrec

Current Issues in Molecular Biology

View PDFchevron_right

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

Sevki Cetinkalp

European Journal of Gastroenterology & Hepatology, 2010

View PDFchevron_right

Current Solutions for Obesity-Related Liver Disorders NAFLD and NASH

Asnat Raziel

View PDFchevron_right

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review

Sintayehu Ambachew

Hepatic Medicine: Evidence and Research

View PDFchevron_right

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

Daniele Nicolini

Liver International, 2011

View PDFchevron_right

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review

Patrice Marche

Biomedicines

View PDFchevron_right

Exploring lipid-related treatment options for the treatment of NASH

Manlio Vinciguerra

Current vascular pharmacology, 2012

View PDFchevron_right

Novel Therapeutic Use of Insulin and Vitamin e in (Nafld) Using Fatty Liver Induced Rats

Mahmoud Mohsen

International Journal of Advanced Research, 2018

View PDFchevron_right

Anti-Diabetic Medications: A promising therapeutic approaches for the Management of NAFLD

Dina Ali

Records of Pharmaceutical and Biomedical Sciences, 2021

View PDFchevron_right

Coagonist of GLP-1 and glucagon receptors ameliorates non-alcoholic fatty liver disease

samadhan kshirsagar

Canadian journal of physiology and pharmacology, 2018

View PDFchevron_right

NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway

Gopabandhu Jena

Naunyn-Schmiedeberg's Archives of Pharmacology, 2019

View PDFchevron_right

The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications

Antonietta Lamazza

Journal of Clinical Medicine

View PDFchevron_right

Insulin resistance: A metabolic pathway to chronic liver disease

Elisabetta Bugianesi, Giulio Marchesini

Hepatology, 2005

View PDFchevron_right

Molecular Mechanisms of NAFLD in Metabolic Syndrome

Piero Portincasa

BioMed Research International, 2015

View PDFchevron_right

Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets

MARTA ALONSO PEÑA

Biomedicines, 2021

View PDFchevron_right

Current treatment paradigms and emerging therapies for NAFLD/NASH

Aditya Upadhyay

Frontiers in Bioscience, 2021

View PDFchevron_right

Nonalcoholic Fatty Liver Disease (NAFLD), a Manifestation of the Metabolic Syndrome: New Perspectives on the Nutritional Therapy

Ana Dâmaso

Endocrinology & Metabolic Syndrome, 2014

View PDFchevron_right

A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?

Mauro Maurantonio

Acta Diabetologica, 2018

View PDFchevron_right

Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD

Christian Fledelius

Journal of Translational Medicine, 2021

View PDFchevron_right

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis

Yoshio Sumida

International Journal of Molecular Sciences

View PDFchevron_right

Insulin Resistance and NAFLD: A Dangerous Liaison beyond the Genetics

Melania Manco

Children (Basel, Switzerland), 2017

View PDFchevron_right

Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression

Jack Leslie

Molecular Metabolism, 2021

View PDFchevron_right

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

Frank Anania

Hepatology, 2010

View PDFchevron_right

Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2

Εμμανουήλ Κουλλιάς

Journal of Clinical and Translational Hepatology

View PDFchevron_right

Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment

Antonino Belfiore

International Journal of Molecular Sciences, 2013

View PDFchevron_right

The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis

Michael Mark

Liver International, 2009

View PDFchevron_right

Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide

Giovanni Targher

Hepatobiliary Surgery and Nutrition

View PDFchevron_right

Preclinical Models of Nonalcoholic Fatty Liver Disease

Prasanna K. Santhekadur

Journal of hepatology, 2017

View PDFchevron_right